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Abstract
Immunization with the vOka vaccine prevents varicella (chickenpox) in children and susceptible adults. The vOka vaccine
strain comprises a mixture of genotypes and, despite attenuation, causes rashes in small numbers of recipients. Like wild-
type virus, the vaccine establishes latency in neuronal tissue and can later reactivate to cause Herpes zoster (shingles).
Using hybridization-based methodologies, we have purified and sequenced vOka directly from skin lesions. We show that
alleles present in the vaccine can be recovered from the lesions and demonstrate the presence of a severe bottleneck
between inoculation and lesion formation. Genotypes in any one lesion appear to be descended from one to three
vaccine-genotypes with a low frequency of novel mutations. No single vOka haplotype and no novel mutations are
consistently present in rashes, indicating that neither new mutations nor recombination with wild type are critical to the
evolution of vOka rashes. Instead, alleles arising from attenuation (i.e., not derived from free-living virus) are present at
lower frequencies in rash genotypes. We identify 11 loci at which the ancestral allele is selected for in vOka rash formation
and show genotypes in rashes that have reactivated from latency cannot be distinguished from rashes occurring imme-
diately after inoculation. We conclude that the vOka vaccine, although heterogeneous, has not evolved to form rashes
through positive selection in themode of a quasispecies, but rather alleles that were essentially neutral during the vaccine
production have been selected against in the human subjects, allowing us to identify key loci for rash formation.
Key words: alphaherpesvirus, viral evolution, pathogenesis.
Introduction
The live varicella vaccine is widely used for prevention of
chickenpox (varicella), caused by the ubiquitous herpesvirus
varicella zoster virus (VZV) (Sharrar et al. 2000; Rentier and
Gershon 2004). The vaccine was derived by standard growth
attenuation techniques of a clinical virus isolate Oka, in semi
permissive culture prior to commercial development and use
(Takahashi et al. 1975). The vaccine virus is heterogeneous
and has accumulated more than 40 mutations during atten-
uation, although only three of these have become universally
fixed (Gomi et al. 2002; Quinlivan et al. 2004, 2006; Loparev
et al. 2007; Breuer and Schmid 2008; Levin et al. 2008). The
vaccine therefore contains a mixture of related viruses, com-
prising a large number of unique haplotypes. In 2–3% of cases,
vaccination is followed by clinically visible rashes or skin le-
sions that are frequently varicella-like, occurring 6–42 days
after inoculation (Sharrar et al. 2000; Goulleret et al. 2010).
Although vaccine varicella rashes are typically mild, these oc-
casionally become severe, particularly in children with under-
lying disorders of innate or adaptive immunity (Kramer et al.
2001; Levy et al. 2003; Chaves et al. 2008; Banovic et al. 2011).
Like wild-type VZV strains (albeit with lower frequency), the
vOka strain can also establish latency in the dorsal root gan-
glia and is capable of reactivating months or years later to
cause herpes zoster that is often indistinguishable from that
caused by wild-type virus (Civen et al. 2009).
We exploit the unusual heterogeneity of this DNA virus
vaccine to examine the influence of population bottlenecks
after inoculation, on rash formation, and reactivation from
latency. As the vOka vaccine strain is known to be attenuated
for replication in skin (Moffat et al. 1998; Arvin 2001; Chen
et al. 2003), rash formation following vaccination could
represent reversion toward the wild phenotype or even
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recombination with wild-type viruses. To enable whole
genome sequencing of vOka virus from opportunistically col-
lected clinical samples of vaccine-associated rashes, we have
adapted a targeted enrichment methodology (shown previ-
ously to recover low copy number virus genomes) that, unlike
methods requiring culture or polymerase chain reaction
(PCR) amplification, does not alter viral population diversity
(Depledge et al. 2011). In this article, we show that the virus
present in vaccine rashes derives from haplotypes present in
the original vaccine mixture and that haplotypes cannot be
segregated by pathogenesis or neurotropism (i.e., those which
enter latency and later reactivate). Moreover, we show that
the frequency of variants in the original vaccine and associ-
ated rashes are preserved by the targeted enrichment
method, unless the sample has previously been cultured.
Finally, we identify both previously undetected alleles segre-
gating in the vaccine and novel mutations that contribute to
viral diversity in skin lesions. Thus, comparison of whole vOka
genome sequences from varicella vaccine preparations, with
sequences obtained from vaccine varicella and zoster lesions
provides insight into VZV evolution in vaccinated individuals.
Results
Optimization of Targeted Enrichment
Archived diagnostic samples of vesicular fluid contain small
amounts (20–150 ng) of extracted total DNA and required
whole-genome amplification (WGA) using the29 polymer-
ase to generate sufficient starting material (2–3mg) for the
SureSelect (SS) custom target capture methodology
(Depledge et al. 2011). Illumina sequencing was performed
on 20 vaccine rash samples collected between 1988 and 2007
and three distinct batches of the VariVax (Merck) VZV vac-
cine from 2008, 2010, and 2012 (table 1). To determine
whether any bias was associated with these methods, we
prepared five sequence libraries (WGA only, SS only, an SS
only replicate, WGA + SS, and direct sequencing without
WGA or SS; supplementary table S1, Supplementary
Material online) from a single batch of VZV vaccine. The
consensus sequences for each sample were identical, while
the correlation of allele frequencies between libraries was high
(Pearson’s product moment R2> 0.93) at sites where total
read depth was over 50 reads per base and where the variant
allele was present on two or more independent reads map-
ping to opposite strands (fig. 1). Deviations in the variant
allele frequency of up to 3.2% were observed but these
were limited to comparisons between enriched and nonen-
riched libraries (fig. 1). This is explained by the fact that read
depths in nonenriched libraries are approximately 20-fold.
A comparison of replicate samples that were independently
enriched showed the standard deviation from the mean allele
frequency, that is, the error of the method to be 0.654%.
Viral DNA was enriched from all vaccine and vaccine-rash
samples with a median of 87.3% on-target reads (table 1).
Read data aligned against the pOKA reference genome
(Gomi et al. 2002) showed a bias against enrichment in GC-
rich regions of the variable region R1–R5 and short region
genomic repeated elements (supplementary fig. S1,
Supplementary Material online). Mean read depths were con-
sistently higher than 1,000 reads per base for all samples
except the nonenriched vaccine. Genome coverage exceeded
97%, except in two cases; samples O27 (90.5%) and K48
(83.8%). The paired-end sequence reads were too short to
adequately map the variable R1–R5 regions and for the ma-
jority of the rashes there was insufficient material to fill these
gaps using PCR and Sanger methods. Sequencing of vaccine
rash samples on the Illumina GAIIx platform gave significantly
more low frequency polymorphic sites (defined as having
a variant allele at <10%) in vaccine rash samples when
compared with samples sequenced on an Illumina MiSeq
(supplementary fig. S2, Supplementary Material online).
Resequencing of three samples for which sufficient DNA
was available (K11, L53, and N13) on both platforms
showed the polymorphisms present in the MiSeq data set
to be a subset of those present in the GAIIx data set with good
correlation between like data sets (K11 r2 = 0.897,
N13 r2 = 0.908, and L53 r2 = 0.897; supplementary fig.
S3, Supplementary Material online). In all cases, the excess
of polymorphic sites in data sets from the GAIIx did not alter
the consensus sequences for these samples but do confirm
that a higher sequencing error rate is associated with the
GAIIx, a finding that has been previously reported
(Minoche et al. 2011; Loman et al. 2012; Quail et al. 2012).
Consensus Sequence Analyses
Animal alphaherpesvirus vaccines have been shown to
recombine with circulating wild type and other attenuated
vaccine viruses with the potential for restoration of viral vir-
ulence (Lee et al. 2012). To exclude this in vOka-based
viruses recovered from rashes, Bayesian (fig. 2) and
Maximum-likelihood trees (not shown) of vaccine and rash
consensus sequences were constructed (Barrett-Muir et al.
2003; Loparev et al. 2007; Sengupta et al. 2007). We found
no significant evidence for the vaccine rashes representing
recombination with wild-type strains. BaTs analysis of the
consensus phylogeny by year of vaccination excluded cluster-
ing of rash sequences by, mode of sample preparation (AI
P= 0.36, MS P= 1.0, MC [high passage in vitro culture] P= 1.0,
MC [low passage culture] P= 0.45, and MC [no culture]
P= 1.0) or disease presentation (zoster or varicella: AI
P= 0.85, PS P= 0.99, MC [varicella] P= 1.0, and MC [zoster]
P= 0.64). The last indicates that viruses that establish latency
and reactivate are not limited to a subset of haplotypes within
the population of vOka variants that cause rashes.
Conservation of Polymorphic Sites in Vaccine
All three sequenced vaccine batches were heterogeneous
with between 235 and 336 polymorphic sites being identified.
Of these, 224 were present in two or more vaccine prepara-
tions (supplementary table S2, Supplementary Material
online) and 207 were shared between all three vaccine prep-
arations, of which 36 had been previously identified by Sanger
or pyrosequencing (Gomi et al. 2002; Loparev et al. 2007;
Quinlivan et al. 2007; Tillieux et al. 2008; Kanda et al. 2011).
These 25–120 single nucleotide polymorphisms (SNPs) were
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limited to single vaccine batches of which 90% were low fre-
quency (<10%). Five sites (12694 and 12779 [open reading
frame {ORF} 10], 31732 [ORF 21], 82225 [ORF 42], and 106710
[ORF 62]) previously reported as polymorphic in Merck vac-
cine batches were fixed for the wild-type allele in all batches
sequenced here (Gomi et al. 2002; Loparev et al. 2007;
Quinlivan et al. 2007; Tillieux et al. 2008). The distribution
of nonsynonymous, synonymous, and noncoding mutations
is shown in figure 3. The vaccine allele frequencies at each of
the 224 sites shared between vaccines were highly conserved
(Pearson’s product moment R2> 0.98), indicating minimal
batch to batch variation at vaccine loci despite each having
been issued in different years and in one case a different
country (table 1; supplementary fig. S4A–C, Supplementary
Material online). Therefore, we infer that the vaccines se-
quenced in this study are genetically compared with the
batches used to inoculate the subjects whose rash viruses
we analyze here. This proposal is also supported by the
high correlation (Pearson’s product moment R2 = 0.83) be-
tween the mean allele frequencies in the vaccines and rash
samples (supplementary fig. S4D, Supplementary Material
online).
Vaccine Rashes Are Mono- or Oligomorphic
Because of the increased proportion of erroneous polymor-
phic sites introduced by GAIIx sequencing, only the variant
data from rashes sequenced on the MiSeq were analyzed
further (i.e., GAIIx data were only included in consensus
level analyses). Between 32 and 112 polymorphisms per
virus were identified in these six uncultured vaccine rashes,
when compared with 235–336 in the vaccine batches. The
lower genetic diversity of rashes can also be quantified by the
proportion of polymorphic sites, being 0.19% for the vaccine,
which is 2–4 times greater than rash diversity (0.03–0.09%). In
vitro tissue culture further reduced rash virus diversity even at
3 passages (supplementary fig. S5, Supplementary Material
online). Of the polymorphisms in the vaccine rashes, 37–93%
(mean 55%) was at the sites of 224 vaccine SNPs (loci poly-
morphic in two or more vaccine samples). Vaccine-allele fre-
quencies at the majority of these sites were lower than in the
Table 1. Samples used in this study.
Sample ID Type Platform % OTR % Genome
Coverage at 50
Country and Year
of Vaccination
Days to Rash
Formation
Varicella vaccine rash
N13a
Uncultured
MiSeq
83.7 97.6 USA-1998 Unknown
VR1 89.4 99.9 Europe-2007 14
VR2 86.4 98.3 UK-2007 16
VR3 81.1 99.9 UK-2006 14
VR4
GAiix
71.0 99.9 UK-2010 Unknown
O27a 92.7 90.5 USA-1999 16
N13* 92.3 96.8 USA-1998 Unknown
A182Ba
High-passage HiSeq
93.4 99.6 USA-1988 16
A185Ba 97.2 99.5 USA-1988 21
Vaccineb
VV10 NL13110 HiSeq 66.8 99.9 UK-2010 N/A
VV12 G007544
MiSeq
89.5 100.0 UK-2012 N/A
VVAGa 1526Xa 88.1 99.9 USA-2009 N/A
Zoster vaccine rash
K11
Uncultured
MiSeq
79.7 99.8 USA-1997 74
L53a 70.5 98.4 USA-1997 131
ZR1 91.0 99.3 UK-2006 330
T61
GAiix
94.8 99.0 USA-2001 90
K11 93.4 98.9 USA-1997 75
L53a 97.2 99.4 USA-1997 131
U14a 73.1 98.2 USA-1997 >1,500
K48a 18.1 83.8 USA-1995 603
R73a 9.6 98.0 USA-unknown Unknown
R3a
Low-passage
57.3 98.0 USA-1999 244
R52a 94.8 98.7 USA-1999 490
T17a 95.7 99.5 USA-2000 310
T25a 60.4 99.4 USA-2000 547
v76 79.3 99.5 USA-1982 630
NOTE.—OTR, on-target reads (i.e., reads mapping to pOka reference genome). Samples in italics were sequenced on both MiSeq and GAiix platforms.
aUnderwent WGA prior to SS.
bNote that all vaccine rashes are derived from VariVax batches used to prevent varicella.
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FIG. 1. WGA and target capture methodologies do not bias population structures. Comparative analyses of allele frequencies at polymorphic sites
between sequencing samples prepared using different methodologies from the same source DNA show high correlation scores and minimal deviations
in frequency. Comparisons are as follows: (A) Direct sequencing (no enrichment) versus SS (enrichment); (B) WGA and SS versus SS; (C) WGA followed
by direct sequencing versus SS; and (D) SS versus SS (repeat).
FIG. 2. Vaccine batches and vaccine rash samples form a monophyletic group with parental pOka strain. The Bayesian phylogenetic tree was inferred
using BEAST and the topology was similar to trees generated using maximum likelihood or constructed using the ORF sequences only (data not shown).
Vaccine batches are indicated by green lines, Vaccine rash sequences are derived from either varicella-like rashes (blue) or zoster-like rashes (red).
Vaccine rash names indicated the sample code (i.e., K11), the year of isolation (i.e., 1997), and the samples status (NPC, uncultured; LPC, minimal
culturing, i.e., less than five passages; and HPC, more than five passages in culture). Representative wild-type VZV sequences from each geographical
clade were also included (pOka, Dumas, M2DR, HJO, and CA123).
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original vOka vaccines (supplementary table S2 and fig. S6,
Supplementary Material online). These data are consistent
with the conclusion that there exist one or more bottlenecks
after inoculation of vaccine and the formation of rashes.
There is a low level of polymorphism at novel loci which
can be attributed to mutation because of the bottleneck.
The rashes sequenced here were fixed for the vaccine allele
at four amino acid coding positions in ORF 62 (105705,
106262, 107252, and 108111) (supplementary table S2,
Supplementary Material online) and their presence may ex-
plain the mild presentation of most vaccine rashes compared
with wild-type rashes (Tsolia et al. 1990; Cohen 2007). In ad-
dition to the 224 vaccine SNPs, we identified a further 39
polymorphic sites present in at least one vaccine and one
vaccine rash and two present in two or more vaccine
rashes but absent in the vaccines(supplementary table S3,
Supplementary Material online). As we know that none of
the rashes arose from the same VariVax vaccine batch
(table 1), the most likely explanation is that for these 41
sites, the vaccine allele is present in the original vaccine at
frequencies that are at the limit of detection by deep
sequencing and therefore are not always detected as
polymorphic.
De Novo Mutations Occurring after Inoculation
A total of 33 de novo mutations were identified in the con-
sensus sequences of all rashes. Sixteen of these were nonsyn-
onymous and occurred in eight rashes (VR1, VR2, A182B, L53,
O27, T25, T17, and T61; table 2). The fixed mutations in rash
A182B, a highly passaged isolate, for which plenty of DNA was
available, were confirmed by Sanger sequencing. In the six
rashes sequenced by the MiSeq method (supplementary
table S4, Supplementary Material online), 67% of the new
mutations that were not fixed were largely present at allele
frequencies of 10% or less and the resequencing of K11, N13,
and L53 confirmed of 62/68 (91.2%) of the new mutations in
these rashes.
Selection for Rash-Forming Alleles
We have shown the segregating allele frequencies in the
Merck vOka vaccine are sufficiently nonvariable between
FIG. 3. Vaccine polymorphic sites are present throughout the genome with notable clusters in ORFS 0, 1, and 62. The circos genome map for vOka
show the relative position of ORFs (green) in the UL (light gray), US (dark gray), and IR/TR (mid gray) regions. Iterative repeat regions R1–R5 are shown as
black bars. The 224 sites (indicated by red bars) at which both parental and vaccine alleles are present appear throughout the genome. The frequency
(0–100%) of the vaccine allele is shown (in blue) at each site. Note that the TR region has been left blank as this is an exact repeat of the IR.
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batches, that most of the vaccine alleles can be considered to
have been present in the particular vaccine batch inoculated
into patients (supplementary fig. S5, Supplementary Material
online). We carried out analyses to evaluate whether there
was any consistent change in allele frequencies between vac-
cine and rashes. This analysis had to take into account the
dramatic loss of genetic diversity in each rash, because it in-
volves large allele-frequency changes from the vaccine. These
large differences cause the average frequencies across all
rashes to deviate from the vaccine frequencies: A pattern
that could be misinterpreted as evidence of consistent
trends, unless appropriate compensation is made. We used
two approaches to allow for this effect: A generalized linear
mixed model, and a generalized linear model with quasi-bi-
nomial error. Both approaches detected a trend for the wild-
type allele to increase in frequency in the rashes (P< 0.001),
the mixed effect model suggesting a significant effect only at
the coding sites (P< 0.001 for nonsynonymous and synony-
mous sites), indicative of selection.
A second analysis was used to identify SNPs with the clear-
est evidence for selection: those at which the vaccine allele
repeatedly changed in frequency, which could indicate loci
with a role in rash formation. Of the 224 vaccine polymorphic
sites, there was statistical power (80%) to perform a bino-
mial analysis for 7: 59591 (ORF31), 94167 (ORF 54), 102002
(intergenic), 105356 (ORF 62), 106001 (ORF 62), 107797 (ORF
62), and 108838 (ORF 62). At six of these sites, five nonsyn-
onymous and one noncoding, the vaccine allele decreased
significantly in the rashes. The vaccine allele increased signif-
icantly at the remaining synonymous site (94167 [ORF 54])
(supplementary table S5, Supplementary Material online).
Using rash genotyping data from the literature and results
from SNP typing of material from 36 additional rashes, we
confirmed there was selection in favor of the ancestral allele
for three of the five nonsynonymous sites, 105356 and 107797
(both ORF 62) which have previously been reported
(Quinlivan et al. 2007), and 106001 (ORF 62; fig. 4). We ana-
lyzed a further nine nonsynonymous, three noncoding and
one synonymous sites (560 [ORF 0], 19036 [ORF 13], 58595
[ORF 31], 87306 [ORF 50], 89734 [ORF 51], 90318 [ORF 51],
97479 [ORF 55], 97748 [ORF 55], 105169 [intergenic], 107599
[ORF 62], 109137 [intergenic], 109200 [intergenic], 115269
[intergenic]) for which SNP typing data from the literature
and/or genotyping of a further 36 rashes provided enough
power to confirm a significant change in allele frequencies
(supplementary table S5, Supplementary Material online).
Of these, there was a significant decrease in the frequency of
the vaccine allele at six nonsynonymous sites: 560 (ORF 0),
19036 (ORF 13), 58595 (ORF 31), 97748 (ORF 55), 97479 (ORF
55), and 105599 (ORF 62); two noncoding: 109137 (ORF 62
promoter) and 105169 (61/62 intergenic); and a significant
increase in the vaccine allele at one synonymous site: 89734
in ORF 51 (fig. 4; supplementary table S5 [Supplementary
Material online]). In addition to positions 105169, 105356,
and 107797 (all ORF 62), which have previously been reported
(Quinlivan et al. 2007), three of the loci under selection, sites
106001 (K1045E) in ORF 62 domain IV, 19036 (G199R) in ORF
13, and 97479 (V495A) in ORF 55 have not previously been
identified as polymorphic in the vaccine. None of the nonsyn-
onymous loci were associated with changes in silico in known
or predicted HLA class 1 epitopes (data not shown).
To evaluate the severity of the population bottleneck, we
provisionally attributed alleles with a frequency of less than
1% in rashes as postbottleneck mutations. Having discarded
these allele frequencies, we modeled the size of the putative
population bottleneck occurring in the vaccine rash after
vaccination by fitting a beta-binomial distribution around
the expectation of the vaccine (estimated from the mean
allele frequencies of the three vaccines). One of the fitted
parameters of the beta-binomial analysis represents the prob-
ability F that two alleles randomly drawn from within a pop-
ulation are identical by descent. The estimated F was 0.79
(0.77–0.81, 95% CI). Matching the allele frequency spectrum,
and this value of F to the output from a stochastic model of
ancestry under exponential growth (we found the best fitting
growth rate corresponding to the observed F, using the MLE
function of R (growth rate r= 0.0703, over 202 generations),
we could explain the data with a model (supplementary fig.
S7, Supplementary Material online) in which most rashes
were likely to be descended from one or two genotypes
Table 2. De novo mutations occurring post-inoculation.
Position
(Dumas)
Wild
Type
Vaccine ORF Amino
Acid
Type Rash
ID
89 T C N/A N/A Noncoding T61
967 G A N/A N/A Noncoding T61
6420 G A ORF 6 A720T Nonsynonymous T61
10540 C T ORF 8 A43V Nonsynonymous T25
12588 A G ORF 10 P143 Nonsynonymous T17
21595 C A ORF 15 T295K Nonsynonymous A182
23756 G T ORF 17 M13I Nonsynonymous A182
37959 G A ORF 22 D1293N Nonsynonymous T61
38111 A C ORF 22 T1343 Nonsynonymous T61
41323 G A ORF 22 E2468K Nonsynonymous L53
44265 T C ORF 25 I37V Nonsynonymous VR1
51190 G A ORF 29 A112T Nonsynonymous O27
51206 G A ORF 29 R117Q Nonsynonymous T61
53993 G A ORF 29 R1046Q Nonsynonymous T61
61629 C T ORF 33 S170 Synonymous T61
62811 T C ORF 34 T273 Synonymous K11
65074 C T ORF 36 Q90* Nonsynonymous T61
67603 A G ORF 37 S510 Synonymous A185
72395 G A ORF 40 D286N Nonsynonymous T61
79183 G A ORF 43 V431I Nonsynonymous VR2
80298 G T N/A N/A Noncoding T17
81940 G A ORF 42 L218 Synonymous T61
82225 A G ORF 42 P123 Synonymous V76
98893 T C ORF 56 L109P Nonsynonymous T61
102976 C T N/A N/A Noncoding R73
106497 T C ORF 62 G879 Synonymous A182
109139 T C N/A N/A Noncoding A182
109749 T G N/A N/A Noncoding A185
109751 T G N/A N/A Noncoding A185
109752 T G N/A N/A Noncoding A185
109754 A G N/A N/A Noncoding A185
109927 A G N/A N/A Noncoding A182
117055 C A ORF 68 T416 Synonymous R52
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(P= 0.41 and 0.51, respectively) and in which the majority of
mutations (97%) occurred after bottleneck.
The availability of material from vOka varicella and zoster
rashes together with the VariVax vaccine strain ancestral to
both provided a unique opportunity to determine whether
vOka rashes caused by viruses reactivating from latency dif-
fered genetically from those causing skin rashes directly, that is,
within 42 days following inoculation (fig. 5). We found no
significant differences in allele frequencies between viruses
directly causing rash after vaccination (fig. 5, routes A and B)
and those that established latency before reactivating to cause
a zoster-rash (fig. 5, route C). The data presented here reflect
only studies of the VariVax vaccine produced by Merck.
Although all licensed vaccines are derived from the same
attenuated vOka strain, the Biken and GSK vaccines have
undergone different manufacturing processes. For example,
the GSK vaccine was plaque purified and is known to have a
higher percentage of vaccine SNPs overall (Kanda et al. 2011).
Although it is reasonable to assume that the findings reported
here apply to vaccine rashes derived from other manufac-
turer’s vaccines, further sequencing is required to confirm this.
Discussion
We have exploited the current varicella immunization pro-
gram in the United States and Europe to investigate the path-
ogenesis of the VZV vOka strain, a DNA virus that establishes
latency in sensory neurons, and have identified a subset of
vaccine loci at which selection of the ancestral allele
influences the development of skin rashes. The VariVax var-
icella vaccine is known to be heterogeneous and genome
sequencing in this study has identified at least 188 polymor-
phic sites additional to those previously recognized, of which
149 are present in all three sequenced vaccine preparations.
Deep sequencing confirms that allele frequencies are highly
correlated between temporally distinct batches (Kanda et al.
2011). Although lack of material prevented us sequencing the
five iterative high G + C repeat regions in the genomes (R1–
R5), these have not been found to differ from wild-type strains
in prior analyses and so are considered unlikely to contribute
to vaccine attenuation (Peters et al. 2006, 2012).
We show that following inoculation, the vaccine-associ-
ated alleles can persist in the viruses recovered from rashes.
However, at most polymorphic vaccine loci, the rash virus is
fixed for either the vaccine or the wild-type allele. A minority
of vaccine loci remains polymorphic in rashes, and in most
cases (72%) the minor allele is present at frequencies below
10% (fig. 3, supplementary table S2, Supplementary Material
online). These data are consistent with a population bottle-
neck following vaccination. From the loss of polymorphism, it
can be estimated that most genetic lineages (F= 0.79) are
descended from the same ancestor in the bottleneck.
Furthermore, in a model of exponential growth since the
bottleneck, this value implies that a typical rash is descended
from one to three ancestral genotypes. There is no evidence
that the mutations that arise following inoculation are re-
sponsible for rash formation: they are rare and do not recur
FIG. 4. Vaccine polymorphic sites under selection. Vaccine polymorphic sites under selection for the ancestral allele in vaccine rashes; 12 positions
(9 nonsynonymous, 3 noncoding) are shown (a–l) in the circos genome plot with a close up of each site showing (top to bottom); the genome position
of alleles (VZV Dumas coordinates), vaccine (upper pie chart), and vaccine rash (bottom pie chart) allele frequencies, the ORF affected, codon
position and mutation, number of samples tested and (F) the FDR-corrected P value for each position. Note that a polymorphic site under selection at
position 89734 is not shown in the figure as it encodes a synonymous mutation.
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across the different rashes. Moreover, unlike some live-atten-
uated animal alphaherpesvirus vaccines, we see no evidence
in our samples of recombination of vOka with wild-type virus
in the rashes (Lee et al. 2012). As they occur at a low frequency
in a population showing evidence of a severe bottleneck, we
argue that low-level polymorphisms observed in the rashes
are most likely to have arisen as mutations during replication
of the vOka virus during the development of a vesicular
lesion. From the allele frequency spectra, we estimated that
97% of mutations occur after bottleneck. Intriguingly, the rash
genotypes show general evidence of selection against the vac-
cine allele: an increase in frequency for the ancestral allele
(supplementary fig. S6, Supplementary Material online).
No one vaccine haplotype is responsible for all rash forma-
tion. Instead, the vOka haplotype is different in every lesion, a
finding that has previously been inferred from limited SNP
typing (Quinlivan et al. 2007). Rash-forming haplotypes are,
however, not completely representative of the virus popula-
tion in the vaccine. Complete viral genome sequences identify
nine nonsynonymous loci in five proteins, at which the an-
cestral allele is most significantly favored in the rashes.
Although two of these loci, positions 107797 (L446P) and
105356 (I1260V) in ORF 62 were already known (Quinlivan
et al. 2007) three loci, 106001 (K1045E) in ORF 62 domain IV,
19036 (E199R) in ORF 13, and 97479 (V495A) in ORF 55 had
not been previously identified by Sanger sequencing as poly-
morphic in the vaccine (fig. 4). Selection of the wild-type allele
at 11 of 12 loci, suggests that vOka rash-causing viruses may
be less attenuated for replication in skin, particularly as we
found no in silico evidence that the observed amino acid
changes are likely to increase escape from host immunity.
The location of four selected positions in ORF 62, the major
viral transactivating protein expressed early in VZV replica-
tion, supports the notion that mutations in this protein are
critical for vaccine Oka attenuation in skin, although the pos-
sibility exists that some of these sites are in linkage disequi-
librium (we were not able to determine this using the current
methodology) while previous studies have shown these SNPs
alone do not account for attenuation (Zerboni et al. 2005;
Cohrs et al. 2006). Position 107797 (L446P in ORF62/71), a
locus that has been consistently observed as the wild-type
allele among vaccine rash isolates, appears to be essential for
vOka rash formation; its position within region 2 of IE62 could
affect the binding efficiency of the transcription complex that
includes IE62, IE63 and host transcription factors (Lynch et al.
2002; Quinlivan et al. 2011). IE62 and IE63 are critical for viral
FIG. 5. Model of possible routes of vOka spread to the skin following inoculation. (1) Live-attenuated VZV vaccine, (2) replication at site of inoculation,
(3) local spread to cause vaccine rash, (4) direct establishment of latency, (5) infection of T cell, (6) mediated transport to cause distal vaccine rash, (7)
vireamic spread to establish latent ganglionic infection, (8) retrograde traversal of sensory neurons to establish latent ganglionic infection, and (9)
reactivation from ganglia to cause zoster. (A), (B), and (C) are rash lesions caused by spread from the site of inoculation, hematogenous spread, and
reactivation from latency. The genotypes of viruses recovered from these lesions cannot be distinguished by route of infection.
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replication in skin and selection of the wild-type allele at
position 101937 in the ORF63 promoter may therefore also
contribute to optimal VZV replication in skin (fig. 4). Position
*130R in ORF0p and I1260L in domain IV of ORF62 occur in
other highly passaged VZV isolates and have been implicated
as contributors to vaccine attenuation. The arginine at posi-
tion *130R in ORF 0, a homolog of HSV UL56, is also present in
VZV Ellen, a strain that is highly attenuated for replication in
skin (Peters et al. 2012). The leucine at position I1260L in
ORF62 has also been shown to evolve during passage of a
wild-type strain, VZV strain 32, in repeated tissue culture
monolayers (Tyler et al. 2007). The selection of the wild-
type isoleucine in most vaccine rashes at this position may
therefore be important for VZV replication in epidermal
tissue. Although the functional significance of position
58595 (I593V) is not known, the SNP is located in the ecto-
domain of gB, which is essential for replication in skin (Zhang
et al. 2010). gB is within a region of the vOka genome that has
been identified by cosmid analysis as contributory to its at-
tenuation for replication in epithelial tissue (Moffat et al.
1998). Positions 97748 (A585T) and 97479 (V495A) in ORF
55p, a homolog of the Herpes Simplex UL5 helicase protein, lie
between predicted helicase domains III and IV, which are
conserved in VZV (Zhu and Weller 1992). ORF 55p functions
together with ORFs 6p and 52p to form the VZV helicase
primase complex, which is essential for viral replication.
Position 19036 (G199R) is located within the ORF 13 thymi-
dylate kinase gene and also plays a part in viral replication.
The vaccine allele at these loci may therefore contribute to
attenuation of vOka strain replication, although this remains
to be confirmed.
Whole-genome sequencing of vaccine-associated rashes
arising soon after vaccination and comparison with those
that followed reactivation from latency provided a unique
opportunity to study the pathogenesis of VZV in its natural
host. We found no difference in vOka haplotypes between
rashes which occur soon after vaccination and those that
occurred following a period of latency and reactivation
from dorsal route ganglia (fig. 5). Thus, from our data, vaccine
variants that persist following inoculation appear equally able
to establish latency and reactivate. Moreover, there is little
evidence for within host selection of neurotropic variants. We
therefore conclude that neither preexisting nor new viral var-
iation is likely to play a part in the establishment of vOka
latency or reactivation (fig. 5).
Finally, it has been suggested previously that vOka vaccine,
because of its heterogeneity, might evolve at a population
level; similarly to RNA viral quasispecies (Gomi et al. 2002;
Peters et al. 2012). For this to happen, the vOka mutation rate
would have to be sufficient to maintain heterogeneity.
Although our findings do indicate the accumulation of mu-
tations as vOka replicates in the skin, mutation rates appear
to be insufficient to recapitulate the diversity that was orig-
inally present in the vaccine. There appears to be even less
opportunity for mutation before the virus reaches the skin
(Moffat et al. 1998; Zerboni et al. 2005). We have found ev-
idence of selection in these data, but it is not selection for new
mutation-generated variants as in a classical quasispecies
model. Instead, it is selection acting on the preexisting varia-
tion that was segregating in the vaccine. It appears that some
vaccine alleles, which had drifted up to intermediate frequen-
cies during the process of vaccine production, are then ac-
tively selected against on the route from inoculation to rash
formation in the human body. These loci are therefore strong
candidates implicated in the genetics of rash formation.
In summary, we used targeted enrichment technologies to
recover sufficient VZV DNA from rashes caused by the vOka
vaccine for whole viral genome sequencing. The method al-
lowed variation in allele frequencies to be accurately quanti-
fied for assessment of genomic populations. We used this
approach to investigate vOka rash formation and the results
also shed light on the pathogenesis of VZV and the live at-
tenuated vaccine strain vOka. We identify at least nine
nonsynonymous residues in five ORFs across the VZV
genome that are probably important for replication of
VOka in the major target organ, skin. From our data, we
find no evidence for population bottlenecks or viral selection
related to latency or reactivation, and no evidence that vOka
evolves as a quasispecies. Taken together, we predict that
while vOka variation plays some role in the development of
varicella-like rashes after inoculation, it plays little or no part
in the pathogenesis of herpes zoster and related reactivation
illnesses. The failure to identify neurotropic vOka strains pro-
vides important data for current efforts to develop vaccines
that do not establish latency.
Materials and Methods
Repository of Data
Consensus sequences for all vaccines and vaccine rash sam-
ples sequenced in this study have been uploaded to the
NR database on Genbank under accession numbers
KF558371-91.
Sample Collection and Ethics
Diagnostic samples from patients with confirmed vaccine-
associated rashes (both varicella- [n= 8] and zoster-like
[n= 12]) collected in the UK and United States between
1988 and 2010, were retrieved from the Breuer lab cryobank.
The clinical specimens, collected as part of standard clinical
practice to genotype vaccine rashes occurring in recipients of
vOka vaccine, were independently obtained from patients
who developed skin rashes following immunization with
the Merck vOka vaccine. All rashes were confirmed as vOka
strain using previously published methods (Larussa et al. 1998;
Parker et al. 2006). Rashes occurring within 42 days of vacci-
nation were classified as varicella like. The exception was one
case, T61, which was reported as a varicella-like rash 90 days
after vaccination. Although by our definition this was thought
to be more likely to be disseminated zoster, the case was
included as varicella like. Cases presenting with the classical
dermatomal rash were diagnosed clinically as herpes zoster.
Samples were stripped of all personal identifiers other than
details of vaccination and the type of rash, no patient infor-
mation was available. The use of these specimens for research
was approved by the East London and City Health Authority
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Research Ethics Committee (P/96/046: Molecular typing of
cases of VZV).
In addition, three batches of the VariVax live-attenuated
VZV Vaccine preparation were collected in 2008 (VVAG
[USA]), 2010 (VV10 [UK]), and 2012 (VV12 [UK]) and
batch and lot numbers used to verify them as independent
preparations (table 1).
Cell Culture
Cultured isolates (table 1) were passaged in melanoma cells
(MeWo) that were propagated in culture media (MEM
[Sigma] supplemented with 10% FBS and 1% nonessential
amino acids). Viruses were harvested for DNA extraction 3–
4 days after inoculation when syncytia was visible.
Library Construction, Targeted Enrichment, and
Sequencing
Total DNA was extracted from each sample using the
QiaAMP DNA mini kit (QIAGEN) according to manufac-
turer’s instructions. DNA quantification was performed
using a NanoDrop spectrophotometer and those with 260/
280 ratios outside the range 1.7–2.1 and 260/230 ratios out
the range 1.8–2.2 were further purified using the Zymoclean
Genomic DNA Clean & Concentrator (Zymo Research Corp.).
WGA using GenomiPhi V2 (GE Healthcare) was performed
using 10 ng of starting material where<50 ng total DNA was
available (table 1). Libraries were constructed as per the stan-
dard SS XT v1.3 (Agilent) and NEBNext (New England
Biolabs) protocols, the latter modified to include a second
PCR amplification step (6 cycles) to enable multiplexing using
standard Illumina barcodes. Enrichment for VZV sequences
was performed as described previously (Depledge et al. 2011).
Samples were sequenced across several Illumina platforms
(GAIIx, HiSeq, and MiSeq) according to availability. Specific
sample preparation and sequencing metrics are shown in
table 1. Concerns about bias introduced by SS and WGA
methodologies were assuaged by resequencing the vaccine
VV12 under multiple conditions (supplementary table S2,
Supplementary Material online) as in all cases, the R2 corre-
lation between allele frequencies exceeded 0.93, and no iden-
tifiable bias was observed regardless of sample treatment.
Genome Assembly and Variant Calling
Each data set was parsed through QUASR (Watson et al.
2013) for duplicate removal and read-trimming (-q 30, -l
50) and subsequently aligned against pOka (AB097933.1)
using BWA (Li and Durbin 2009). Resulting alignments were
processed using SAMTools (Li et al. 2009) to generate pileup
files for each sample. A consensus sequence for each data set
was called with the QUASR module pileupConsensus and a
50% frequency threshold (i.e., no ambiguities were included).
Variant profiling for each data set was performed using
VarScan v2.2.11 (Koboldt et al. 2012) with the following pa-
rameters: basecall quality20, read depth50, independent
reads supporting minor allele2 per strand. In addition, var-
iant calls showing directional strand bias0.85 were excluded
from further analyses. Consensus sequences were generated
for each rash sample but iterative repeat regions (ORIS R1, R2,
R3, R4, and R5) and the terminal repeat region were trimmed
before analysis.
Consensus Sequence Analyses
DNA sequences were aligned using the program Mafft, v6
(Katoh 2002) with alignments checked manually; no inser-
tions or deletions were inferred from the alignment. Prior to
further analysis the VZV repeat regions R1, R2, R3, R4, R5, and
OriS (Davison and Scott 1986; Hondo and Yogo 1988) were
removed as these could not be accurately mapped given the
limited DNA available. Bayesian phylogenetic trees were in-
ferred using the program Beast v1.7.2 (Drummond et al.
2012). Two independent Monte Carlo-Markov chains were
run for 50,000,000 iterations for the whole genome (minus
repeat regions) with a thinning of 1,000. The most appropri-
ate model of nucleotide substitution was selected using the
program jModelTest (Posada 2008), which identified a gen-
eral-time-reversible model of nucleotide substitution with a
gamma-shaped rate distribution and a proportion of invari-
able sites (GTR + g + I) as being the best site model. The
phylogeny was reconstructed under a number of different
tree priors including the Bayesian skyline, constant, and ex-
ponential growth models. Runs were checked for conver-
gence and that an effective sample size of at least 200 had
been achieved for all parameters. Runs were combined using
LogCombiner v1.6.1, and TreeAnnotator v1.6.1 was used to
obtain the highest clade credibility tree and posterior proba-
bilities per node. Maximum likelihood phylogenies were also
inferred using Mega v5.05 (Tamura et al. 2011) under the
same model of evolution. All trees were visualized and
drawn using Figtree v1.3.1 (http://tree.bio.ed.ac.uk/software/
figtree/, last accessed September 17, 2013). We tested for
evidence of recombination using the programs GARD and
SBP (Pond et al. 2006), and the BootScan method contained
in the RDP3 program (Martin et al. 2010). The program BaTS
(Parker et al. 2008) was used to test for an association be-
tween the Bayes-inferred phylogeny and the vaccine rash
phenotype (varicella-like or zoster-like). BaTS estimates the
association using the association index (Wang et al. 2001),
parsimony score (Slatkin and Maddison 1989), and maximum
monophyletic clade statistics.
Statistical Analyses
To compensate for intrinsic differences in the sequencing
technologies used, their respective error profiles and fold dif-
ferences between the mean read depths of individual samples,
we identified a minimal criterion for defining biallelic sites
that segregate our samples 1) total read depth 50, 2) the
vaccine allele must appear2 independent reads mapping to
each strand, 3) the vaccine frequency must be 1%, and 4)
the segregating site must appear in 2 vaccines and/or vac-
cine rash samples at the earlier-mentioned criteria. These cri-
teria were applied only to data obtained using the MiSeq and
HiSeq platforms and yielded a total of 368 sites that were
segregating across the vaccines and vaccine rashes. The allele
frequencies at these sites in the GAIIx-derived data were
406
Depledge et al. . doi:10.1093/molbev/mst210 MBE
subsequently included if the vaccine allele was a match (i.e.,
not a sequencing error). The frequency of the vaccine allele in
vaccine rash samples at the majority of these sites was effec-
tively binary, either 0% or 100%. 224 sites are polymorphic in
two or more vaccine batches while sites that were polymor-
phic in just the one vaccine were excluded from further anal-
ysis. Subsequently, we calculated the mean vaccine allele
frequency for each of these polymorphic sites in the three
sequenced vaccines, VV10, VV12, and VVAG. We investigated
any consistent changes in allele frequency from the vaccine to
the vaccine rashes. The variance in vaccine rash allele frequen-
cies appeared higher than expected and we modeled this over
dispersion around the expectation (the rash frequency) using
two approaches: a generalized linear mixed model and a gen-
eralized linear model with quasi-binomial error. With the rash
allele frequencies as the response variable, we compared four
models in the generalized linear model: no intercept, inter-
cept only, coding/noncoding sites, and synonymous/nonsyn-
onymous/intergenic region.
The majority of the 224 vaccine polymorphic sites in the
vaccine rashes were effectively binary, that is, fixed for either
the vaccine or the wild-type allele. Consequently, to identify
any specific sites where the change in allele frequency cannot
be explained by genetic drift alone, we compared the propor-
tion of vaccine rashes with the vaccine allele to the expected
proportion (vaccine mean). We estimated the effect size
(based upon the mean vaccine allele frequency in the vaccines
and the proportion of vaccine rashes fixed for the vaccine
allele) and power (Cohen 1988), and identified those sites for
which there was80% power to compare the vaccine rashes
with the vaccine. Finally, we applied two-tailed binomial exact
tests to those sites with 80% power with the probability of
“success” equal to the mean vaccine allele frequency in the
vaccines. We corrected for multiple analyses using FDR
(Hochberg and Benjamini 1990).
We also used the power analyses to identify a set of the
vaccine polymorphic sites that could be analyzed with SNP
typing of an additional 36 vaccine rashes, which were readily
available and/or the inclusion of previously published data
(Loparev et al. 2007; Quinlivan et al. 2007; Thiele et al.
2011). Using binomial exact tests, we compared the propor-
tion of the vaccine allele at these sites in all of the vaccine
rashes (sequenced, SNP typed, and previously published) with
the mean frequency in the sequenced vaccines (with a FDR
correction for multiple analyses). In addition, we reanalyzed
those sites that we showed to have sufficient power from the
sequencing (discussed earlier) with the addition of SNP typed
and previously published data. Finally, we used generalized
linear modeling with binomial error to identify any differences
between varicella and zoster vaccine rashes at the 224 vaccine
polymorphic sites. All binomial tests and the generalized
linear modeling were performed in R (www.r-project.org/
index.html, last accessed September 17, 2013). Effect size
and power calculations were done using the “pwr” package
in R, and the modeling of rash allele frequencies used the lme4
and VGAM packages.
To infer the size of the putative population bottleneck
occurring in the vaccine rash after vaccination, we fitted a
beta-binomial distribution around the expectation of the vac-
cine (estimated from the mean allele frequencies of the three
vaccines). It has been shown that the distribution of allele
frequencies (assuming that loci are biallelic) under genetic
drift can be modeled as a beta-binomial distribution
(Balding 2003). The probability that two alleles randomly
drawn are identical by descent, F, is directly related to the
correlation parameter of the beta distribution. We fitted the
beta-binomial using the R package VGAM. Finally, we mod-
eled the rash sample as the product of a bottleneck followed
by exponential growth. We found the best fitting growth rate
corresponding to the observed F, using the MLE function of R.
The expected value of F was calculated in a model of postbot-
tleneck exponential growth to a nominal end point of mil-
lion-fold increase. F was calculated as 1(1-1/Ni), where Ni
is the population size in generation i. We then used a Monte
Carlo simulation of ancestry with these population sizes, by
artificially drawing the ancestors of a sample back through the
201 preceding generations. The sample size matched our av-
erage coverage (1,942 reads). From 1,000 such possible ances-
tries, we generated the allele frequency spectra that would
occur for mutations occurring post bottleneck and prebot-
tleneck. The mutations were uniformly distributed across all
ancestors (in each category). We matched the allele frequency
spectrum of alleles that were not detectable in the vaccines,
presumably new mutations occurring postbottleneck, and
compared FIS with the output from a stochastic model of
ancestry with exponential growth (implemented in R).
Additional SNP typing
SNP typing at positions 59591, 90318, 94167, 97479, 97748,
and 106001 was conducted on an additional 36 vaccine rash
samples derived from a range of patients across the UK and
the United States. PCRs comprising 30 amplification cycles
were performed in 12.5ml reactions using either the Extensor
2x Master Mix (Thermo Fisher Scientific, Hanover Park, IL) or
the Takara Ex Taq Kit (Clontech Laboratories, Mountain
View, CA). Each reaction of 2ml was run on 1% agarose gel
and visualized on a Biorad Molecular Imager Gel Doc XR
+ Imagine System (Bio-Rad Laboratories, CA). PCR products
were cleaned up using ExoSap-It from USB (Affymetric,
Cleveland, OH) according to manufacturer’s specifications
and sequenced on the 3130X/Genetic Analyzer from ABI
(Life technologies, Foster City, CA). The sequence traces
were analyzed with the Sequencher program from Gene
Codes Corporation (Ann Arbor, MI). All primers used for
SNP typing are shown in supplementary table S6
(Supplementary Material online).
Selection of Low-Level De Novo Variants
Mutations acquired postinoculation (i.e., de novo) were iden-
tified in data sets derived from the MiSeq under the following
criteria; the variant allele occurred in 2 reads on opposite
strands with a read depth 50 and a frequency exceeding 1%.
To identify whether there was any selection operating upon
the new mutations in the vaccine rashes, we used the
Kolmogorov–Smirnov test to compare the total number of
407
Evolution and Pathogenesis of VZV Vaccine . doi:10.1093/molbev/mst210 MBE
nonsynonymous mutations with the sum of the synonymous
and noncoding mutations in all of the rashes.
In Silico Epitope Prediction
As fitness selection is often linked to immune escape, the
nonsynonymous sites under selection 59591, 97479, 97748,
105356, 106001, 107599, and 107797 were examined using
Metaserver (MacNamara and Kadolsky 2009) and Epipred
(Heckerman et al. 2006) to identify HLA class 1 epitopes
mapping to the vaccine and wild-type peptides and to calcu-
late the predicted binding scores. No significant hits were
reported for any site.
Supplementary Material
Supplementary figures S1–S7 and tables S1–S6 are available at
Molecular Biology and Evolution online (http://www.mbe.
oxfordjournals.org/).
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